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OBJECTIVE — The purpose of this study was to examine the performance of the UK Pro-
spective Diabetes Study (UKPDS) Risk Engine (version 3) and the Framingham risk equations
(2008)inestimatingcardiovasculardisease(CVD)incidenceinthreepopulations:1)individuals
with known diabetes; 2) individuals with nondiabetic hyperglycemia, deﬁned as A1C 6.0%;
and 3) individuals with normoglycemia deﬁned as A1C 6.0%.
RESEARCH DESIGN AND METHODS — This was a population-based prospective
cohort (European Prospective Investigation of Cancer-Norfolk). Participants aged 40–79 years re-
cruited from U.K. general practices attended a health examination (1993–1998) and were followed
for CVD events/death until April 2007. CVD risk estimates were calculated for 10,137 individuals.
RESULTS — Over 10.1 years, there were 69 CVD events in the diabetes group (25.4%), 160
in the hyperglycemia group (17.7%), and 732 in the normoglycemia group (8.2%). Estimated
CVD 10-year risk in the diabetes group was 33 and 37% using the UKPDS and Framingham
equations, respectively. In the hyperglycemia group, estimated CVD risks were 31 and 22%,
respectively, and for the normoglycemia group risks were 20 and 14%, respectively. There were
no signiﬁcant differences in the ability of the risk equations to discriminate between individuals
at different risk of CVD events in each subgroup; both equations overestimated CVD risk. The
Framingham equations performed better in the hyperglycemia and normoglycemia groups as
they did not overestimate risk as much as the UKPDS Risk Engine, and they classiﬁed more
participants correctly.
CONCLUSIONS — Both the UKPDS Risk Engine and Framingham risk equations were
moderately effective at ranking individuals and are therefore suitable for resource prioritization.
However, both overestimated true risk, which is important when one is using scores to com-
municate prognostic information to individuals.
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I
ndividualswith type2diabeteshavea
two to four times increased risk of
cardiovascular disease (CVD) com-
pared with those without diabetes (1).
Multifactorial interventions aimed to
reduce hyperglycemia, hypertension,
and hypercholesterolemia are effective
for reducing the risk of cardiovascular
andmicrovasculareventsindiabeticindi-
viduals(2,3).Multivariateequationssuch
as the Framingham equations are used
to estimate CVD risk to target therapy to
thosewiththehighestabsoluteriskandto
provide patients and practitioners with
prognostic information. However, al-
though some studies have concluded that
the Framingham risk equations for esti-
mating CVD risk provide acceptable re-
sultswhenappliedtopopulationsoutside
North America (4), others have suggested
that they are not applicable in those with
a particularly low or high risk (5), includ-
ing individuals with diabetes (6). The UK
ProspectiveDiabetesStudy(UKPDS)Risk
Engine is a type 2 diabetes-speciﬁc risk
calculator that includes A1C as well as
traditional CVD risk factors. Version 2 of
the Risk Engine estimates coronary heart
disease risk and stroke risk separately. In
version 3, equations have been derived
that estimate CVD risk directly (7). This
novel risk equation has been validated in
the Collaborative Atorvastatin Diabetes
Study (CARDS) cohort (8), which was a
primary prevention trial, and showed
good predictive ability. The CARDS trial
cohort is not necessarily as widely gener-
alizable as a true population-based sam-
ple. Thus, in this article we examined the
performance of the UKPDS Risk Engine
(version 3) and the Framingham risk
equations (2008) in estimating CVD inci-
dence in three population subgroups: 1)
individuals with known diabetes; 2) in-
dividuals with nondiabetic hyperglyce-
mia (A1C 6.0%); and 3) individuals
with A1C 6.0% (normoglycemia).
RESEARCH DESIGN AND
METHODS— European Prospective
Investigation of Cancer (EPIC)-Norfolk is
a prospective cohort study in which men
and women aged 40–79 years were re-
cruited from general practices in the Nor-
folk region of the U.K. Full details of the
population are reported elsewhere (9). In
brief, between 1993 and 1998, 25,639
individuals attended a baseline health ex-
amination. This included anthropometric
and blood pressure measurements and
completion of a general health question-
naire, with questions on personal and
family history of disease, medication, and
lifestyle factors. Participants were asked
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
Fromthe
1MRCEpidemiologyUnit,Cambridge,U.K.;the
2DiabetesTrialsUnit,OxfordCentreforDiabetes,
Endocrinology and Metabolism, Oxford, U.K.; and the
3Department of Clinical Gerontology, University
of Cambridge, Cambridge, U.K.
Corresponding author: Simon Grifﬁn, simon.grifﬁn@mrc-epid.cam.ac.uk.
Received 22 October 2008 and accepted 16 December 2008.
Published ahead of print at http://care.diabetesjournals.org on 29 December 2008. DOI: 10.2337/dc08-1918.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cardiovascular and Metabolic Risk
ORIGINAL ARTICLE
708 DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009to indicate whether they were a current
smoker, ex-smoker, or never smoker.
They were also asked whether a doctor
had ever told them that they had any of
the conditions contained in a list that in-
cluded diabetes, heart attack, and stroke.
In addition, baseline diabetes status was
also ascertained by 1) a self-report of dia-
betes medication; 2) diabetes medication
brought to the baseline health check; 3)
indication of a modiﬁcation in diet in the
past year because of diabetes; or 4) indi-
cation of following a diet for diabetes.
Nonfasting blood samples were obtained,
and starting in 1995 when funding be-
came available, A1C was measured on
fresh EDTA blood samples using high-
performance liquid chromatography
(Diamat automated glycated hemoglobin
analyzer; Bio-Rad, Hemel Hempstead,
U.K.).
The population in the Norfolk area is
healthier than the general U.K. popula-
tion with a standardized mortality ratio of
94 (source: Ofﬁce for National Statistics).
However, the EPIC-Norfolk cohort is
similartoanationallyrepresentativesam-
ple for anthropometric variables, blood
pressure, and serum lipids (9).
We report results for follow-up to
April2007.Participantswerefollowedfor
a median of 10.1 years. All EPIC-Norfolk
participants were ﬂagged for death certi-
ﬁcationattheOfﬁceofNationalStatistics,
andvitalstatuswasobtainedfortheentire
cohort. Trained nosologists coded death
certiﬁcates according to the ICD-9 or
ICD-10. Cardiovascular death (stroke,
coronary heart disease, peripheral vascu-
lardisease,andothervascularcauses)was
deﬁned in those whose underlying cause
of death was coded as ICD-9 400–448 or
ICD-10I10–I79.Participantsadmittedto
a hospital were identiﬁed by their Na-
tional Health Service number. Hospitals
were linked to the East Norfolk Health
Authority database, which identiﬁes all
hospital contacts throughout England
and Wales for Norfolk residents. Partici-
pants were identiﬁed as having a CVD
event during follow-up if they had a hos-
pital admission and/or died with CVD as
the underlying cause. Previous validation
studies in our cohort indicated high spec-
iﬁcity of such case ascertainment (10).
Estimation of cardiovascular risk
The 10-year absolute risk of CVD was es-
timated for each participant using the
UKPDS Risk Engine version 3.0 (7). This
is a type 2 diabetes-speciﬁc risk assess-
ment tool that deﬁnes CVD as the ﬁrst
eventtooccuroffatalornonfatalmyocar-
dial infarction, sudden cardiac death,
other incident ischemic heart disease, fa-
tal or nonfatal stroke, and peripheral vas-
cular disease death. Similarly, we applied
the Framingham CVD risk equations
(2008) (11) for each participant, which
deﬁnes CVD as the ﬁrst event to occur of
myocardial infarction (including silent
andunrecognizedmyocardialinfarction),
death from coronary heart disease (CHD)
(sudden or nonsudden), CHD (myocar-
dial infarction and CHD death plus an-
gina pectoris and coronary insufﬁciency),
stroke, transient ischemic attack, conges-
tive heart failure, and peripheral vascular
disease.
Statistical analysis
We excluded individuals with self-
reportedCVDatbaseline(n1,106)and
those with missing values for one or more
of the variables (ethnicity, smoking sta-
tus, total cholesterol, HDL cholesterol,
systolic blood pressure, and A1C) used to
calculate the Framingham and UKPDS
Risk Engine CVD risk estimates (n 
548). Because A1C measurement started
approximately half-way through the data
collection period, only 42% of the origi-
nal sample had A1C values at baseline.
Baseline characteristics were summa-
rized separately in population subgroups
using means and percentages. The sub-
groups encompassed 1) individuals with
known diabetes; 2) individuals with non-
diabetic hyperglycemia, deﬁned as A1C
6.0%; and 3) individuals with A1C
6.0% (normoglycemia). We calculated
the observed mean CVD risk and the es-
timated CVD risk using the UKPDS Risk
Engine and Framingham equations. We
examined their performance by 1) com-
paring the area under the receiver operat-
ing characteristic curve (aROC) using a
nonparametricalgorithm(12)toassessdis-
crimination, 2) computing a Bayes infor-
mation criterion (BIC) statistic to assess
the global ﬁt of the models, and 3) exam-
ining the proportion of men and women
who would be reclassiﬁed into higher- or
lower-risk categories between the two
equations, using the Net Reclassiﬁcation
Improvement (NRI) statistic (13). We as-
sessedthecalibrationofeachequationus-
ing a goodness-of-ﬁt test statistic. All
analyses were performed in the whole
EPIC-Norfolk population and separately
by sex. Sensitivity analyses were per-
formed to examine possible differences in
baseline characteristics between partici-
pants with and without A1C data.
All analyses were completed using
Stata (version 10.0; StataCorp, College
Station,TX).TheEPIC-Norfolkstudywas
approved by the Norfolk Local Research
Ethics Committee, and participants gave
written consent before the ﬁrst health
check.
RESULTS— The dataset included
4,424 men and 5,713 women for whom
wehadcompletedataavailable,including
A1C. The cumulative incidence rate of
CVD was 9.8 per 1,000 person-years.
Baseline characteristics for the EPIC-
Norfolk cohort, by population subgroup,
are shown in Table 1. Individuals with
prevalent diabetes had the highest mean
age, and there was a higher proportion of
men compared with other groups. Simi-
larly, individuals with diabetes had the
highest mean BMI, systolic blood pres-
sure,andA1Candwerethemostlikelyto
report statin use but had the lowest pro-
portion of current smokers. Individuals
with nondiabetic hyperglycemia had the
highest mean total cholesterol and LDL
cholesterol.
Overamedianof10.1yearsoffollow-
up, there were 69 CVD events in the 272
individuals with diabetes (25.4%), 160 in
the 906 with nondiabetic hyperglycemia
(17.7%), and 732 in the 8,959 with nor-
moglycemia (8.2%) (Table 1). The esti-
mated CVD 10-year risk in individuals
with diabetes was 33 and 37% using the
UKPDS and Framingham equations, re-
spectively(Table2).Inthehyperglycemia
group, estimated CVD risk was 31 and
22%, respectively, and in the normogly-
cemia group, estimated CVD risk was 20
and 14%, respectively.
The aROC for individuals with diabe-
tes in EPIC-Norfolk was 0.72 for the
UKPDS Risk Engine and 0.73 for the Fra-
mingham equations (Table 2). There was
no statistically signiﬁcant difference in
theirdiscrimination(P0.58).Similarly,
the aROC for individuals with nondia-
betic hyperglycemia was 0.68 for the UK-
PDS Risk Engine and 0.66 for the
Framingham equations, with no signiﬁ-
cant difference in discrimination (P 
0.16). For normoglycemic individuals,
theaROCfortheUKPDSRiskEnginewas
0.77 and for the Framingham equations
was0.77,withnoevidenceofadifference
in the ability of the equations to discrim-
inatebetweenthosewhohadaCVDevent
and those who did not (P  0.38). The
shapes of each set of ROC curves were
roughly similar in each subgroup (data not
shown). The BIC value was similar for both
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group, indicating good global model ﬁt.
Both the Framingham risk equations
and the UKPDS Risk Engine had good to
excellent ability to correctly identify indi-
viduals who would develop CVD using a
cutoffpointof20%inallthreesubgroups
(Table 2). In the diabetes group, for ex-
ample, the sensitivity was 0.94 for the
RiskEngineand0.86fortheFramingham
equations. However, both equations had
poor speciﬁcity. The speciﬁcity was high-
est in the diabetes group (31 and 30% for
the Risk Engine and Framingham equa-
tions, respectively) and lowest in the nor-
moglycemia group, with the Risk Engine
only achieving 15%.
Reclassiﬁcations are summarized in
Table 3. The NRI refers to the net gain in
correctreclassiﬁcationandwascalculated
using notation presented by Pencina et al.
(13). A positive NRI indicates that the
UKPDS Risk Engine shows an improve-
ment in classiﬁcation over the Framing-
ham equations, whereas a negative NRI
corresponds to an improvement in classiﬁ-
cation of the Framingham equations over
the UKPDS Risk Engine. The NRI for the
diabetes group was 5.8% (P  0.17), indi-
cating that there was no signiﬁcant im-
provement in classiﬁcation using either
equation. However, for those with nondia-
betic hyperglycemia (NRI 14.0%, P 
0.004) and normoglycemia (NRI 12.4%,
P0.001),theFraminghamriskequations
classiﬁed more participants correctly than
the UKPDS Risk Engine.
The goodness-of-ﬁt test statistics
were nonsigniﬁcant for the UKPDS Risk
Engine in the diabetes (P  0.67) and
hyperglycemia (P  0.12) groups and for
the Framingham equations in the hyper-
glycemia group (P  0.12), indicating
good calibration. However, the UKPDS
Risk Engine was not well calibrated to the
EPIC-Norfolk population in the normo-
glycemia group (P  0.001) and the Fra-
mingham risk equations were not well
calibrated in the diabetes (P  0.02) and
normoglycemia (P  0.001) groups.
Results stratiﬁed by sex were broadly
similar to the overall ﬁndings. In the dia-
betesgrouptheoverestimationofriskwas
not so pronounced in women, but there
remained no signiﬁcant difference in the
ability of the two sets of risk equations to
discriminate between those at high risk;
Table 1—Baseline characteristics by population subgroup and incident CVD events, EPIC-Norfolk cohort, U.K., 1993–2007
Characteristic
Individuals with
prevalent diabetes
Individuals with
nondiabetic hyperglycemia
Normoglycemic
individuals
P value for
difference†
n 272 906 8,959
Mean age (years) 62.8  8.6 62.6  8.4 56.6  9.6 0.001
Women 129 (47.4) 498 (55.0) 5,086 (56.8) 0.006
Social class*
I to III nonmanual 156 (58.9) 497 (56.0) 5,485 (61.2)
III manual to V 109 (41.1) 391 (44.0) 3,329 (37.2) 0.003
Caucasian 272 (100.0) 904 (99.8) 8,919 (99.6) 0.990
Mean BMI (kg/m²) 27.8  5.0 27.5  4.5 26.0  3.8 0.001
Mean total cholesterol (mmol/l) 6.0  1.2 6.4  1.2 6.1  1.1 0.001
Mean HDL (mmol/l) 1.4  0.4 1.4  0.4 1.5  0.4 0.457
Mean LDL (mmol/l) 3.8  1.0 4.1  1.1 3.9  1.0 0.001
Mean systolic blood pressure (mmHg) 141.4  19.0 140.8  17.6 133.5  17.9 0.001
Statin use 10 (3.7) 18 (2.0) 94 (1.1) 0.001
Current smoker 23 (8.5) 155 (17.1) 1,028 (11.5) 0.001
Mean A1C (%) 7.5  2.0 6.4  0.9 5.1  0.5 0.001
CVD events 69 (25.4) 160 (17.7) 732 (8.2) 0.001
DataaremeansSDorn(%).n10,137.*Numbersmaynotadduptototalduetomissingvalues.†Groupswerecomparedusingone-wayANOVAforcontinuous
variables and 
2 tests for categorical variables.
Table 2—Actual and estimated CVD risk, aROC curve, and BIC for the UKPDS and Framingham CVD risk equations in each population
subgroup, EPIC-Norfolk cohort, U.K. 1993–2007
Individuals with
prevalent diabetes
Individuals with
nondiabetic hyperglycemia
Normoglycemic
individuals
n 272 906 8,959
Actual CVD event rate 25.4 17.7 8.2
Estimated CVD 10-year risk: UKPDS Risk Engine [% (95% CI)] 33.2 (28.1–38.5) 30.5 (25.9–35.4) 20.4 (17.0–24.2)
Estimated CVD 10-year risk: Framingham equations (%) 36.7 22.3 14.4
aROC (95% CI) for the UKPDS Risk Engine 0.72 (0.65–0.78) 0.68 (0.63–0.72) 0.77 (0.76–0.79)
aROC (95% CI) for the Framingham equations 0.73 (0.66–0.78) 0.66 (0.62–0.71) 0.77 (0.76–0.79)
Sensitivity/speciﬁcity of the UKPDS Risk Engine* 0.94/0.31 0.94/0.22 0.97/0.15
Sensitivity/speciﬁcity of the Framingham equations* 0.86/0.30 0.90/0.26 0.96/0.20
BIC for the UKPDS Risk Engine 288 807 4,444
BIC for the Framingham equations 285 816 4,405
*Using a cutoff point of 0.20, e.g., 20% absolute risk of a CVD event in the next 10 years.
CVD estimation in EPIC-Norfolk
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cant in both sexes. Similarly, for hyper-
glycemic men, results were the same as
the overall ﬁndings. In hyperglycemic
women, however, the UKPDS Risk En-
gine was signiﬁcantly better (P  0.02) at
discriminating between individuals at
high risk, although the NRI was nonsig-
niﬁcant (P  0.93). In normoglycemic
women, the NRI became nonsigniﬁcant,
indicating that that both sets of equations
classiﬁed EPIC-Norfolk participants
equallywell.Conversely,inmen,theFra-
mingham equations was signiﬁcantly bet-
ter at discriminating between individuals
at high risk and classiﬁed more partici-
pants correctly than the UKPDS Risk En-
gine (NRI 25%, P  0.001).
Sensitivity analyses demonstrated
that there were differences between par-
ticipants with and without A1C data for
certain baseline characteristics, e.g., indi-
viduals without A1C data were signiﬁ-
cantly older and had higher total
cholesterol levels and systolic blood pres-
sure. However, the absolute difference
between the two groups did not affect the
relative performance of the Framingham
equations, which was the same in the two
groups (data not shown).
CONCLUSIONS — In all population
subgroups in the EPIC-Norfolk cohort,
both the UKPDS Risk Engine and Fra-
mingham risk equations were moderately
effective for identifying those at high risk
(discrimination). If the purpose of a risk
estimate is to rank individuals according
to absolute risk to target therapy to those
at greatest risk, then our results conﬁrm
that CVD risk equations can assist with
the targeting of therapy in individuals
with diabetes.
In addition to their ranking function,
risk equations can be used to communi-
cate prognostic information or accurate
estimation of the likely absolute beneﬁt
from a therapeutic intervention to pa-
tients and practitioners. In this instance,
theprecisecomputationofabsoluteriskis
important. Because both equations over-
estimated the risk of CVD in all sub-
groups,ourresultssuggestthatcareisstill
needed when equations are being used to
communicate risk information. Although
theriskofaCVDeventwasoverestimated
using both risk tools, it was encouraging
that the proportion of participants with
true-positive results correctly identiﬁed
(sensitivity) was high in all three sub-
groups. The Framingham equations per-
formed better in the hyperglycemic and
normoglycemic groups as they did not
overestimate risk by as much as the
UKPDS Risk Engine, and they classiﬁed
more participants correctly.
These results are unsurprising be-
cause the UKPDS Risk Engine was devel-
oped speciﬁcally for use in those with
diabetes, and its use to estimate risk in
other populations was exploratory (14).
Similarly, the overestimation of the Fra-
mingham risk equations conﬁrms previ-
ous ﬁndings in populations with low
disease rates (5). However, the deﬁnition
of CVD used in this analysis contains
fewerendpointsthanthedeﬁnitiongiven
by the Framingham equations, account-
ing for some of the overestimation.
The predictive ability of both the
UKPDS and Framingham risk equations
in the EPIC-Norfolk cohort is lower than
that reported in the original populations
in which they were developed (11,14).
Thisistobeexpectedgivenchangesinthe
nature and distribution of cardiovascular
risk factors over time, both within and
betweenpopulations.Asystematicreview
of27externalvaliditystudiesshowedthat
the performance of the Framingham risk
equations varies considerably among dif-
ferent countries and ethnic groups. Pre-
dicted-to-observed ratios ranged from an
underprediction of 0.43 in a higher-risk
population, to overprediction of 2.87 in
lower-risk populations (5). Results from
diabeticpopulationsindicatethattheFra-
mingham equations underestimates risk
by as much as a half (15–18), contrasting
with results from this study in which Fra-
mingham equations overestimated CVD
risk in individuals with diabetes. This
ﬁnding may reﬂect the moderate CVD
rates in the relatively healthy Norfolk re-
gion. Our results on the discrimination of
theFraminghamequationsinthediabetic
subgroup (aROC 0.73) are higher than
those of a similar study, which validated
Table 3—CVD risk classiﬁcation comparing the UKPDS Risk Engine and Framingham risk equation models, including the NRI, for each
population subgroup, EPIC-Norfolk cohort, U.K., 1993–2007
UKPDS risk categories
Framingham risk categories
Total 0–10% 10–20% 20%
Participants with diabetes
0–10% 17 (89.5) 3 (5.9) 0 (0.0) 20 (7.4)
10–20% 2 (10.5) 34 (66.7) 9 (4.5) 45 (16.5)
20% 0 (0.0) 14 (27.5) 193 (95.5) 207 (76.1)
NRI (%), P value comparing UKPDS and
Framingham models
5.8, 0.171
Participants with nondiabetic hyperglycemia
0–10% 46 (26.1) 0 (0.0) 0 (0.0) 46 (5.1)
10–20% 122 (69.3) 74 (24.3) 1 (0.2) 197 (21.7)
20% 8 (4.6) 230 (75.7) 425 (99.8) 663 (73.2)
NRI (%), P value comparing UKPDS and
Framingham models
14.0, 0.004
Participants with normoglycemia
0–10% 2,177 (51.3) 10 (0.4) 0 (0.0) 2,187 (24.4)
10–20% 2,002 (47.2) 972 (38.1) 36 (1.7) 3,010 (33.6)
20% 62 (1.5) 1,570 (61.5) 2,130 (98.3) 3,762 (42.0)
NRI (%), P value comparing UKPDS and
Framingham models
12.4%,  0.001
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individuals with newly diagnosed diabe-
tes (aROC 0.67) (18).
There are few diabetes-speciﬁc CVD
risk equations available and a large num-
ber of equations for the general popula-
tion. Whether the latter can be used in a
subgroup of individuals with diabetes re-
mainsuncertain.TheUKPDSRiskEngine
wastheﬁrstcoronaryriskcalculatortobe
developed from a cohort with type 2 dia-
betes (14). Although it showed good pre-
dictive ability, individuals from the
original study were not wholly represen-
tative of the general population. The au-
thors advised that calculation of CVD risk
in individuals who do not have newly di-
agnosed type 2 diabetes or who are aged
25 or 65 years should be completed
with caution. The UKPDS equations have
since been updated for use among indi-
viduals with established type 2 diabetes
(version 3) (7), and the Risk Engine has
been externally validated using data from
the CARDS study (3,8). However, be-
cause the characteristics of the CARDS
population are similar to that of the UK-
PDS, caution should still be used when
calculating CVD risk in individuals out-
side the 25- to 65-year age range. The
moderate predictive value of the UKPDS
equation in the EPIC-Norfolk cohort can
perhaps be attributed in part to the size-
able proportion of individuals aged 65
years (25%) in this cohort. As statin use
was not common in the EPIC-Norfolk co-
hortatbaseline,thisisunlikelytoaccount
for the overestimation in risk using the
UKPDS equation.
Measurement error in determining
cardiovascular disease outcomes may
have been present in our analyses. Four-
ﬁfthsoftheCVDeventswerenonfataland
were identiﬁed by linking records with
hospital admission data. Although we
could ascertain all deaths in the EPIC-
Norfolk cohort, we could not identify all
nonfatal cardiovascular events. However,
previous validation studies in our cohort
indicate high speciﬁcity of such case as-
certainment (10). Hospital admission
data probably underestimate nonfatal
CVD events because not all of them result
in hospital admission. Nevertheless, this
method probably identiﬁes nonfatal
events of most clinical importance, e.g.,
those resulting in hospital admission.
The Framingham and EPIC-Norfolk
CVD deﬁnitions included angina as an
outcome, whereas the UKPDS deﬁnition
did not. However, the CVD outcomes
werelargelysimilar,andthisisunlikelyto
be a large source of bias. In terms of cal-
culating the UKPDS risk equation, we did
not have data on atrial ﬁbrillation in the
EPIC-Norfolk cohort. Because the num-
ber of participants with atrial ﬁbrillation
was very low in the UKPDS cohort
(1%), the presence of atrial ﬁbrillation
is unlikely to affect our ﬁndings.
EPIC-Norfolk is a predominantly
Caucasiancohort,whichlimitsthegener-
alizability of our ﬁndings on the perfor-
mance of the two equations to other
ethnic groups. In addition, both equa-
tions are based on information that might
not be readily available in less developed
health care settings, and the equations
mayneedtobemodiﬁedaccordingly.De-
spite the large number of participants in
EPIC-Norfolk,therewasalowprevalence
of individuals with diabetes at baseline
(3%). This fact may have limited our abil-
ity to fully evaluate the predictive value of
the risk estimates in this group, and fur-
ther testing in other cohorts is recom-
mended. The EPIC-Norfolk cohort may
also have included a small proportion of
individuals with type 1 diabetes. How-
ever,thenumberofparticipantsreceiving
insulin therapy was low, indicating that
thiswasunlikelytoaffecttheoverallﬁnd-
ings. It is also possible that the nondia-
betic hyperglycemic and normoglycemic
groups contained some individuals with
prevalent but undiagnosed diabetes.
However, the UKPDS Risk Engine is used
to estimate CVD in those with clinically
diagnosed diabetes, so this is unlikely to
be a major source of bias.
In this large, population-based co-
hort, we found that the UKPDS Risk En-
gine and Framingham risk equations
performed reasonably well for identifying
those with a high CVD risk (discrimina-
tion). However, both equations overesti-
mated risk. Although CVD risk estimates
may have a function in ranking individu-
als to target therapy to those at greatest
risk, using equations to communicate ab-
solute risk information needs careful
consideration. The Framingham risk
equations should continue to be used in
thegeneralpopulationas1)theequations
did not overestimate risk by as much as
the UKPDS Risk Engine in the normogly-
cemia and hyperglycemia groups and 2)
theyclassiﬁedmoreparticipantscorrectly
than the UKPDS Risk Engine, which is
pertinent for statin prescribing. Further
testing of the UKPDS (version 3) Risk En-
gine in other diabetic cohorts is required
before it can replace Framingham-based
methods of risk assessment in this group.
Itisclearthatuncriticalapplicationofrisk
estimates may mislead patients and prac-
titioners(19).Itmaythereforebevaluable
to focus on making sure that the tools we
currently have for risk prediction are ap-
plied more broadly and routinely
throughout clinical practice to address
the gap between the promise of CVD pre-
vention and its reality (20). In an attempt
to reduce CVD risk, the precision of the
instrumentandhowitisusedcanbecon-
sidered of equal importance. Thus, there
isstillaneedforfurtherresearchintopro-
vider and patient perceptions of CVD risk
(21,22) and the impact of knowledge of
risk on behaviors.
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